Active Substance & Generic Molecule Directory
Abiraterone Acetate in Malaysia: Registered Brands, Dosages & Price Comparison
Directory of all approved pharmaceutical brands containing Abiraterone Acetate registered with the National Pharmaceutical Regulatory Agency (NPRA) / Ministry of Health Malaysia (KKM).
10
Registered Brands
Availability in Malaysia:10 Prescription (MAL-A)
Showing 10 of 10 registered brands
| MAL Reg No | Brand Formulation Name | Strength / Dosage | Classification | Registration Holder | Action |
|---|---|---|---|---|---|
| MAL19056010AZ | Abiratred Abiraterone Acetate Tablets 250mg | 250 mg | Prescription (MAL-A) | Dr. Reddy`s Laboratories Malaysia Sdn. Bhd. | Compare → |
| MAL25036015AZ | Abrone 250mg Film Coated Tablets | 250.000 mg | Prescription (MAL-A) | NOVUGEN ONCOLOGY SDN. BHD. | Compare → |
| MAL25036014AZ | Abrone 500mg Film Coated Tablets | 500.000 mg | Prescription (MAL-A) | NOVUGEN ONCOLOGY SDN. BHD. | Compare → |
| MAL22056055ACZ | ABYTONE (Abiraterone Acetate) Tablets 250mg | 250.00 mg | Prescription (MAL-A) | ACCORD HEALTHCARE SDN.BHD. | Compare → |
| MAL20126019AZ | Arabitro 250mg Tablets | 250 mg | Prescription (MAL-A) | Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd. | Compare → |
| MAL21116026ACZ | ARTESTO (Abiraterone Acetate Tablets USP 250mg) | 250 mg | Prescription (MAL-A) | DUOPHARMA HAPI SDN. BHD. | Compare → |
| MAL25096021ACZ | Estatiga 500mg Film-Coated Tablets | 500 mg | Prescription (MAL-A) | Wellesta Healthcare Sdn. Bhd. | Compare → |
| MAL20076027AZ | Xbira 250mg (Abiraterone Acetate Tablets USP 250mg) | 250 mg 710 mg | Prescription (MAL-A) | CIPLA MALAYSIA SDN BHD | Compare → |
| MAL25086010AZ | Xbira 500mg (Abiraterone Acetate Film-Coated Tablets USP 500 mg) | 500 mg | Prescription (MAL-A) | CIPLA MALAYSIA SDN BHD | Compare → |
| MAL20116008ACZ | ZYTIGA 500mg Film-Coated Tablet | 500 mg | Prescription (MAL-A) | JOHNSON & JOHNSON SDN. BHD. | Compare → |
Generic Bioequivalence & Drug Substitution in Malaysia
Generic medications registered under NPRA contain the identical active pharmaceutical ingredient (API) in identical dosage strength and route of administration as the originator brand. NPRA requires rigorous bioequivalence (BE) studies demonstrating that generic drugs deliver the exact therapeutic effect. Always confirm with your doctor or community pharmacist before switching between prescription brands.